Main > > >ANGINA PECTORIS. *

---

Cardio.>Angina. Chronic. Treat.: Ranola- zine ER Tablets. Brand.
EU Approval Date : 2008. 04.
USA Approval Sate: 2006. 01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.18.




Cardio.>Angina. Chronic. Treat.: Ranola- zine ER Tablets. Generic.
USA Launch Date: 2019. 05.26.
(*) Company: Teva Pharma.
UpDate: 2019. 11.04.




Cardio.>Angina. Refractory Angina. Treat.: Percutaneous Implant.
EU Approval Date: 2013. 11.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




Cardio.>Angina. Treat.: NitroGlycerin Spray.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.11.




Cardio.>Angina. Treat.: NitroGlycerin SubLingual Powder.
USA Approval Date: 2016. 06.14.
USA Launch Date : 2016. 09.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.18.




Cardio.>Angina. Unstable Angina. Ischemic Complications. Prevention:
Enoxaparin Sodium Injection. BRAND.
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi-Aventis U.S. LLC.
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Cardio.>Angina. Unstable Angina. Ischemic Complications. Prevention:
Enoxaparin Sodium Injection. GENERIC.
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals.
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Cardio.>Aspirin+OmeprAzole Delayed Release Tablets.
Indications:
Aspirin Component:
. Reducing the combined risk of death
and nonfatal MI in patients with a
previous MI or unstable angina
pectoris
. Reducing the combined risk of MI and
sudden death in patients with chronic
stable angina pectoris
. Use in patients who have undergone
revascularization procedures (Coronary
Artery Bypass Graft [CABG] or
Percutaneous Transluminal Coronary
Angioplasty [PTCA]) when there is a
pre-existing condition for which
aspirin is already indicated
OmeprAzole Component:
. decreasing the risk of developing
aspirin-associated gastric ulcers in
patients at risk for developing
aspirin-associated gastric ulcers due
to age (≥ 55) or documented history of
gastric ulcers.
USA Approval Date: 2016. 09.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Cardio.>HyperTriGlyceridemia. (HTG). Icosapent Ethyl [Ethyl EicosaPentaenoic Acid (E-EPA)]. Indications:
Indication (1): HTG>Treat.>Diet+ Icosa-
pent Ethyl Capsules.
Indication (2): CardioVascular (CV)
Events (in Adult Pa-
tients with HTG & CV
DIS. or Diabetes) RISK
Reduction: Statin+Icosa-
pent Ethyl Capsules.
CV Events:
- Coronary Revascularization.
- Myocardial Infarction (MI)
- Stroke
- Unstable Angina requiring hospitali-
zation.
CA Approval Date (2): 2020. 01.02.
USA Approval Date (1): 2012.
USA Approval Date (2): 2019. 12.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.03.




Cardio.>Implantable Cardiac Monitor (ICM) & Patient Alerting System for Acute Coronary Syndromes (ACSs.).
Implantation: Like Pacemaker in less
than 1 hour under local
anesthetic.
Indication : Patients have had prior
ACS events including
Myocardial Infarctions
(Heart Attacks) or
unstable Angina and who
remain at high risk for
recurrent ACS events.
EU Approval Date : 2010. 09.21.
USA Approval Date: 2018. 04.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.07.




Treat.: Acebutolol.HCl Capsules. Generic
(*) Company: Mylan
UpDate: 2019. 02.18.




Treat.: Amiodarone.HCl Inj. Generic
(*) Company : Fresenius Kabi USA
Web-Site:
products.fresenius-kabi.us/product-
4.html
UpDate: 2019. 02.18.




Treat.: Amlodipine Besylate. Tab. Brand.
(*) Company : Pfizer.
TradeMark: Norvasc.
UpDate: 2019. 03.27.




Treat.: Amlodipine Besylate. Tab. Gene-
ric.
(*) Company: Teva Pharma.
UpDate: 2019. 03.27.




Treat.: Atenolol Tablets. Generic.
(*) Company: Mylan
UpDate: 2019. 02.18.




Treat.: NitroGlycerin SubLingual Aerosol
USA Approval Date: 2006. 11.02.
(*) TradeMark : NitroMist
Web-Site : www.nitromist.com
UpDate: 2019. 02.18.




With Unstable Angina. Ischemic Compli-
cations. Prophylaxis: Enoxaparin Na
Inj. Generic.
USA Approval Date: 2019. 12.05.
(*) Company: Meitheal Pharmaceuticals.
UpDate: 2019. 12.11.




With Unstable Angina. Undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA). AntiCoagulant. Biva-
lirudin for Inj. Brand.
(*) Company : Medicines Co.
Patent : Expired.
TradeMark: Angiomax
Web-Site : www.angiomax.com/
UpDate: 2019. 04.11.




With Unstable Angina. Undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA). AntiCoagulant. Biva-
lirudin for Inj. Generics.
USA Launch Date: 2017. 06.06.
(*) Company: Dr. Reddy s Labs.
UpDate: 2019. 04.11.


>ANGINA PECTORIS. *'s products
This section has no products